University of Pennyslvania and Caltech are in line for exits when Stanford’s online education spinout lists on the New York Stock Exchange.

Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.

Caltech spinout Talis Biomedical has raised more than $220m in an initial public offering on the Nasdaq Global Market.

NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.

The share price of Columbia University's cellular oncology drug developer, backed by Osage University Partners, has doubled since it floated.

Stanford spinout Bolt Biotherapeutics has raised more than twice as much as originally planned in an offering that also provided exits for corporates Pfizer, Novo and Fan Fung.

Immunocore has raised more than $258m in an upsized offering and an additional $15m in a concurrent private placement.

Harvard-linked Sana brought in nearly four times as much in proceeds as originally planned and saw shares surge 40% on the first day of trading.

Virginia Tech spinout Landos Biopharma priced its shares at $16 to raise $100m and will use proceeds to advance the development of two treatments for inflammatory bowel disease.

Harvard-linked Sana Biotechnology will raise as much as $397m if it floats at the upper end and underwriters take up the greenshoe option.